Valion Bio, Inc. VBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -8.88M | -7.51M | -6.34M |
| Total Depreciation and Amortization | -- | -- | 5.00K | 275.00K | 276.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 1.33M | 1.34M | 839.00K |
| Change in Net Operating Assets | -- | -- | 452.00K | -189.00K | -262.00K |
| Cash from Operations | -- | -- | -7.00M | -6.08M | -5.49M |
| Capital Expenditure | -- | -- | -38.00K | -13.00K | -3.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -667.00K | -543.00K | -543.00K |
| Cash from Investing | -- | -- | -705.00K | -556.00K | -546.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 2.45M | 3.56M | 3.15M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 16.21M | 4.34M | 585.00K |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -308.00K | -5.00K | -207.00K |
| Cash from Financing | -- | -- | 18.35M | 7.89M | 3.53M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 10.64M | 1.26M | -2.51M |